Table 1.
Baseline demographics and disease characteristics.
| sc IFN β-1a (n = 104) | Teriflunomide 7 mg (n = 109) | Teriflunomide 14 mg (n = 111) | |
|---|---|---|---|
| Age, years, mean (SD) | 37.0 (10.6) | 35.2 (9.2) | 36.8 (10.3) |
| Female, n (%) | 71 (68.3) | 70 (64.2) | 78 (70.3) |
| Caucasian, n (%) | 104 (100) | 109 (100) | 111 (100) |
| Time since first symptoms of MS, years, mean (SD) | 7.7 (7.6) | 7.0 (6.9) | 6.6 (7.6) |
| No. of relapses within previous year, mean (SD) | 1.2 (1.0) | 1.3 (0.8) | 1.4 (0.8) |
| Relapsing-remitting MS, n (%) | 104 (100) | 109 (100) | 108 (97.3)a |
| Use of DMT in previous 2 years, n (%) | 25 (24.0) | 23 (21.1) | 13 (11.7) |
| Baseline EDSS score, mean (SD) | 2.0 (1.2) | 2.0 (1.2) | 2.3 (1.4) |
| Baseline FIS score, mean (SD) | 34.2 (32.7) | 39.5 (34.8) | 42.5 (37.8) |
DMT: disease-modifying therapy; EDSS: Expanded Disability Status Scale; FIS: Fatigue Impact Scale; IFN: interferon; MS: multiple sclerosis; sc: subcutaneous; SD: standard deviation.
Randomized population (n = 324).
a
Secondary progressive MS (n = 1); progressive relapsing MS (n = 2).